עישון

1. Novel Technologies to assess Gut Health Claims for Carbohydrates Subthema: 2 - Characterization of biological effects of carbohydratesNaam trekker: UJF Tietge / HJ VerkadeAffiliatie: UMC Groningen/Dept. of PediatricsContactgegevens: u.j.f.tietge@med.umcg.nl

2. gut health programming programming e.g. SCFA e.g. SCFA e.g. SCFA food microbiota food food microbiota microbiota - direct effects - modulation of programmed risk We are programmmed for disease breast milk vs. formula feeding aging disease in utero General theme: different carbohydrates have differential effects on the balance between health and disease by affecting the intestine at all stages of life

3. Increasing gut health with carbohydrates at all stages of life Mouse models Human studies Gut-flora-dependent metabolism of dietary PC and atherosclerosis programming Deliverables Deliverables • in vivo screening • platform • biomarkers • (disease-causing signatures • of metabolites/ bacterial • products) • novel CHs to test in humans • leads for health claims • in vivo screening routine for • CHs with human relevance • health claims based on • established mechanisms • novel biomarkers of disease • including microbiota • establish novel CHs as • functional food conventional vs. germ-free vs. selective re-constitution/ transplantation • Disease models: • - atherosclerosis • - diabetes (type I and II) • - NAFLD/NASH • intest. Inflammation Short-term intervention: - children (lean/obese) - adults (young/elderly/IBD) (13)CH Techniques: - atherosclerosis quantitation - GTT/ITT/clamps - Histology - histology/clinical symptoms - stable isotopes to quantitate metabolic fluxes - characterization microbiota - barrier function • Techniques: • GTT/clamp • biomarkers • stable isotope techniques • SCFA measurements • - histology/clinical symptoms • - sampling capsule to characterize: • microbiota • barrier function ZN Wang et al. Nature472, 57-63(2011) Close links to themes 1, 3 and 4

4. Mouse models programming Deliverables • in vivo screening • platform • biomarkers • (disease-causing signatures • of metabolites/ bacterial • products) • novel CHs to test in humans • leads for health claims conventional vs. germ-free vs. selective re-constitution/ transplantation • Disease models: • - atherosclerosis • - diabetes (type I and II) • - NAFLD/NASH • intest. Inflammation Techniques: - atherosclerosis quantitation - GTT/ITT/clamps - Histology - histology/clinical symptoms - stable isotopes to quantitate metabolic fluxes - characterization microbiota - barrier function Increasing gut health with carbohydrates at all stages of life (13)CH

5. Gut-flora-dependent metabolism of dietary PC and atherosclerosis ZN Wang et al. Nature472, 57-63(2011)

6. Human studies Deliverables • in vivo screening routine for • CHs with human relevance • health claims based on • established mechanisms • novel biomarkers of disease • including microbiota • establish novel CHs as • functional food Short-term intervention: - children (lean/obese) - adults (young/elderly/IBD) • Techniques: • GTT/clamp • biomarkers • stable isotope techniques • SCFA measurements • - histology/clinical symptoms • - sampling capsule to characterize: • microbiota • barrier function (13)CH